山东新华制药股份获缬沙坦胶囊药品注册证书

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Valsartan capsules, which will enhance the company's cardiovascular disease treatment product line and improve its overall competitiveness [1] Group 1 - The company has been granted a drug registration certificate for Valsartan capsules, which is expected to be effective from December 2025 [1] - The approval of Valsartan capsules is part of the company's strategy to diversify its product offerings in the cardiovascular disease sector [1] - This development is anticipated to strengthen the company's market position and competitive edge in the pharmaceutical industry [1]